KROS
Keros Therapeutics Inc

1,239
Mkt Cap
$532.55M
Volume
660,545.00
52W High
$72.37
52W Low
$9.12
PE Ratio
11.33
KROS Fundamentals
Price
$17.48
Prev Close
$17.50
Open
$17.71
50D MA
$15.94
Beta
0.88
Avg. Volume
1.06M
EPS (Annual)
-$5.00
P/B
1.01
Rev/Employee
$21,005.92
Loading...
Loading...
News
all
press releases
Buy These 5 Best Value Stocks to Make the Most of P/B Ratio
Discover five low P/B picks like STNE that are undervalued and show solid growth potential based on value-focused filters.
Zacks·23h ago
News Placeholder
More News
News Placeholder
KROS or NVZMY: Which Is the Better Value Stock Right Now?
KROS vs. NVZMY: Which Stock Is the Better Value Option?
Zacks·3d ago
News Placeholder
How Much Upside is Left in Keros Therapeutics (KROS)? Wall Street Analysts Think 34.24%
The consensus price target hints at a 34.2% upside potential for Keros Therapeutics (KROS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks·3d ago
News Placeholder
Keros Therapeutics (NASDAQ:KROS) Shares Gap Down - Here's Why
Keros Therapeutics (NASDAQ:KROS) Shares Gap Down - Time to Sell...
MarketBeat·9d ago
News Placeholder
Los Angeles Capital Management LLC Purchases New Stake in Keros Therapeutics, Inc. $KROS
Los Angeles Capital Management LLC acquired a new position in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) in the 2nd quarter, according to the company in its most recent filing with the...
MarketBeat·13d ago
News Placeholder
Connor Clark & Lunn Investment Management Ltd. Boosts Stake in Keros Therapeutics, Inc. $KROS
Connor Clark & Lunn Investment Management Ltd. raised its holdings in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 107.4% during the 2nd quarter, according to the company in its most...
MarketBeat·13d ago
News Placeholder
Keros Therapeutics' (KROS) Outperform Rating Reiterated at Oppenheimer
Oppenheimer restated an "outperform" rating and issued a $27.00 target price (up previously from $23.00) on shares of Keros Therapeutics in a research report on Wednesday...
MarketBeat·16d ago
News Placeholder
5 Undervalued Stocks That Are Poised for Growth in November
Five undervalued picks - including StoneCo and MillerKnoll - shine with strong growth prospects and low price-to-book ratios this November.
Zacks·16d ago
News Placeholder
Wells Fargo & Company Lowers Keros Therapeutics (NASDAQ:KROS) Price Target to $23.00
Wells Fargo & Company reduced their target price on Keros Therapeutics from $26.00 to $23.00 and set an "overweight" rating on the stock in a research report on Tuesday...
MarketBeat·17d ago
News Placeholder
KROS vs. ARGX: Which Stock Is the Better Value Option?
KROS vs. ARGX: Which Stock Is the Better Value Option?
Zacks·19d ago

Latest KROS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.